RRIG1 mediates effects of retinoic acid receptor β2 on tumor cell growth and gene expression through binding to and inhibition of RhoA

Cancer Research

Volumn 66, Issue 14, 2006, Pages 7111-7118

  Liang, Zheng D ^a   Lippman, Scott M ^a   Wu, Tsung Teh ^a   Lotan, Reuben ^a   Xu, Xiao Chun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLOOXYGENASE 2; F ACTIN; GUANOSINE TRIPHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN RETINOID RECEPTOR INDUCED GENE 1; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA2; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL INVASION; CELL MEMBRANE; CELL PROLIFERATION; CHROMOSOME 9Q; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ESOPHAGUS CANCER; GENE EXPRESSION; GENE LOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; RESTRICTION FRAGMENT; TUMOR GROWTH;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CLONING, MOLECULAR; COS CELLS; DNA, COMPLEMENTARY; ESOPHAGEAL NEOPLASMS; HUMANS; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; RECEPTORS, RETINOIC ACID; RHOA GTP-BINDING PROTEIN; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 33746885425     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0812     Document Type: Article

References (47)

1. Xu XC, Lotan R. Aberrant expression and function of retinoid receptors in cancer. In: Nau H, Blaner WS, editors. Handbook of experimental pharmacology. New York: Springer; 1999. p.323-43.
2. Soprano DR, Qin P, Soprano KJ. Retinoic acid receptors and cancers. Annu Rev Nutr 2004;24:201-21.
3. Lotan K, Xu XC, Lippman SM, et al. Suppression of retinoic acid receptor-β in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995;332:1405-10.
4. Geradts J, Chen J-Y, Russell EK, Yankaskas JK, Nieves L, Minna JD. Human lung cancer cell lines exhibit resistance to retinoic acid treatment. Cell Growth Differ 1993;4:799-809.
5. Xu XC, Liu X, Tahara E, Lippman SM, Lotan R. Expression and up-regulation of retinoic acid receptor-β is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines. Cancer Res 1999;59:2477-83.
6. 2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res 2002;62:2455-61.
7. Houle B, Rochette-Egly C, Bradley WE. Tumor-suppressive effect of the retinoic acid receptor β in human epidermoid lung cancer cells. Proc Natl Acad Sci U S A 1993;90:985-9.
8. 2 transgene. FASEB J 1996;10:1091-7.
9. 2 inhibition of metastasis in mouse mammary gland xenografts. Breast Cancer Res Treat 2002;72:79-88.
10. 2 in F9 cells results in the loss of retinoic acid-associated growth arrest. J Biol Chem 1999;274:26783-8.
11. Li M, Song S, Lippman SM, et al. Induction of retinoic acid receptor-β suppresses cyclooxygenase-2 expression in esophageal cancer cells. Oncogene 2002;21:411-8.
12. 2 expression. Oncogene 2005;24:8268-76.
13. Song S, Xu XC. Effect of benzo[a]pyrene diol epoxide on expression of retinoic acid receptor-β in immortalized esophageal epithelial cells and esophageal cancer cells. Biochem Biophys Res Commun 2001;281:872-7.
14. Toulouse A, Loubeau M, Morin J, Pappas JJ, Wu J, Bradley WE. RARβ involvement in enhancement of lung tumor cell immunogenicity revealed by array analysis. FASEB J 2000;14:1224-32.
15. 2 target genes in F9 teratocarcinoma cells. Mol Cancer Res 2003;1:619-30.
16. Xu XC, Zhang W, Song S, Lotan R, Lippman SM. Identification of RAR-β-regulated genes using cDNA microarray. Cancer Epidemiol Biomarkers Prev 2002;11:A120.
17. Aoki T, Mori T, Du X, Nisihira T, Matsubara T, Nakamura Y. Allelotype study of esophageal carcinoma Genes Chromosomes Cancer 1994;10:177-82.
18. Devlin J, Elder PA, Gabra H, Steel CM, Knowles MA. High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci. Br J Cancer 1996;73:420-3.
19. Simoneau M, LaRue H, Aboulkassim TO, Meyer F, Moore L, Fradet Y. Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene 2000;19:6317-23.
20. Liang Z, Lippman SM, Kawabe A, Shimada Y, Xu XC. Identification of benzo(a)pyrene diol epoxide-binding DNA fragments using DNA immunoprecipitation technique. Cancer Res 2003;63:1470-4.
21. Wan H, Oridate N, Lotan D, Hong WK, Lotan R. Overexpression of retinoic acid receptor-β in head and neck squamous cell carcinoma cells increases their sensitivity to retinoid-induced suppression of squamous differentiation by retinoids. Cancer Res 1999;59:3518-26.
22. Qiu H, Zhang W, El-Naggar AK, et al. Loss of retinoic acid receptor-β expression is an early event during esophageal carcinogenesis. Am J Pathol 1999;155:1519-23.
23. Xu XC, Shappell SB, Liang Z, et al. Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and up-regulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia 2003;5:121-7.
24. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992;70:389-99.
25. Alexandropoulos K, Cheng G, Baltimore D. Proline-rich sequences that bind to Src homology 3 domains with individual specificities. Proc Natl Acad Sci U S A 1995;92:3110-4.
26. Burridge K, Wennerberg K. Rho and Rac take center stage. Cell 2004;116:167-79.
27. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002;420:629-35.
28. Hoang MV, Whelan MC, Senger DR. Rho activity critically and selectively regulates endothelial cell organization during angiogenesis. Proc Natl Acad Sci U S A 2004;101:1874-9.
29. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 1995;269:1270-2.
30. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002;2:133-42.
31. Vial E, Sahai E, Marshall CJ. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 2003;4:67-79.
32. Pierrat B, Simonen M, Cueto M, Mestan J, Ferrigno P, Heim J. SH3GLB, a new endophilin-related protein family featuring an SH3 domain. Genomics 2001;71:222-34.
33. Jackson P, Baltimore D. N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J 1989;8:449-56.
34. Seidel-Dugan C, Meyer BE, Thomas SM, Brugge JS. Effects of SH2 and SH3 deletions on the functional activities of wild-type and transforming variants of c-Src. Mol Cell Biol 1992;12:1835-45.
35. Hirai H, Varmus HE. Mutations in src homology regions 2 and 3 of activated chicken c-src that result in preferential transformation of mouse or chicken cells. Proc Natl Acad Sci U S A 1990;87:8592-6.
36. Miyazaki K, Senga T, Matsuda S, et al. Critical amino acid substitutions in the Src SH3 domain that convert c-Src to be oncogenic. Biochem Biophys Res Commun 1999;263:759-64.
37. Cheng CH, Yu KC, Chen HL, et al. Blockade of v-Src-stimulated tumor formation by the Src homology 3 domain of Crk-associated substrate (Cas). FEBS Lett 2004;557:221-7.
38. Groysman M, Nagano M, Shaanan B, Katzav S. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation. Oncogene 1998;17:1597-606.
39. Avizienyte E, Fincham VJ, Brunton VG, Frame MC. Src SH3/2 domain-mediated peripheral accumulation of Src and phospho-myosin is linked to deregulation of E-cadherin and the epithelial-mesenchymal transition. Mol Biol Cell 2004;15:2794-803.
40. Benitah SA, Valeron PF, van Aelst L, Marshall CJ, Lacal JC. Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta 2004;1705:121-32.
41. Gomez del Pulgar T, Benitah SA, Valeron PF, Espina C, Lacal JC. Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays 2005;27:602-13.
42. Sahai E, Marshall CJ. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signaling and extracellular proteolysis. Nat Cell Biol 2003;5:711-9.
43. Qiu RG, Chen J, McCormick F, Symons M. A role for Rho in Ras transformation. Proc Natl Acad Sci U S A 1995;92:11781-5.
44. Yoshioka K, Nakamori S, Itoh K. Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Res 1999;59:2004-10.
45. Fritz G, Just I, Kaina B. Rho GTPases are overexpressed in human tumors. Int J Cancer 1999;81:682-7.
46. Pille JY, Denoyelle C, Varet J, et al. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther 2005;11:267-74.
47. Benitah SA, Valeron PF, Lacal JC. ROCK and nuclear factor-κB- dependent activation of cyclooxygenase-2 by Rho GTPases: effects on tumor growth and therapeutic consequences. Mol Biol Cell 2003;14:3041-54.